AstraZeneca, MedImmune has entered into four new biotech partnering with the University of Cambridge, building further on their existing partnership.
The latest collaborations reinforce AstraZeneca’s commitment to creating a permeable research infrastructure in Cambridge following the company’s decision to locate one of its three global research and development centres and its global headquarters in the city that has been home to MedImmune’s biologics research laboratories for 25 years.
The agreements build on the existing strategic partnership between AstraZeneca, MedImmune and the University of Cambridge, which includes a substantial oncology research programme and co-location of AstraZeneca scientists at the Cancer Research UK Cambridge Institute, the largest single facility conducting cancer research in the University of Cambridge.
The four agreements involve: Neuroscience research
A three-year collaboration between AstraZeneca, MedImmune and the University of Cambridge will focus on advancing research and development in neurodegenerative diseases, an area with a large unmet medical need.
Scientists from all three parties will collectively address gaps in drug discovery, translational biomarkers and personalised healthcare approaches for diseases such as Alzheimer’s, Parkinson’s and multiple sclerosis.
The University of Cambridge will contribute world-leading expertise in disease biology, experimental models and tissue samples, while AstraZeneca and MedImmune will provide access to molecular tools, screening capabilities and leading drug development expertise to enable novel target and biomarker discovery and validation.
The research will be carried out at MedImmune and the University of Cambridge laboratories, with opportunities for investigators to work alongside each other and share knowledge.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with AstraZeneca
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity